IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

NCT07408635 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Stage III Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

Interventions

DRUG: IBI363 + Chemotherapy

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China